NCT03163186|CompletedDMC
Transradial Versus Transfemoral Arterial Access in Liver Cancer Embolization: Randomized Trial to Assess Patient Outcomes and Satisfaction (BEST ACCESS Trial).
ACCESS
Loading search results
ACCESS
Sponsor study identifier
observational
55
1 country
1
Study Start
December 1, 2015
Actual (reported)Primary Completion
April 20, 2016
Actual (reported)Study Completion
August 18, 2016
Actual (reported)To evaluate the safety, advantages, and appropriateness of performing transarterial hepatic emobolization of liver cancer via arterial access from the radial artery versus conventional transfemoral arterial access. The procedures that will be followed utilizing arterial access include transarterial chemoembolization (TACE), specifically performed for hepatocellular carcinoma, and transarterial embolization (TAE) which is performed for types of liver tumors such as carcinoid tumors or liver metastases.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
August 18, 2016
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
December 1, 2015
Actual (reported)April 20, 2016
Actual (reported)August 18, 2016
Actual (reported)May 19, 2017
Actual (reported)May 22, 2017
Actual (reported)To assess potential patient preference for the performance of hepatic embolization procedures via transradial versus transfemoral approach.
Record of patient response via administered questionnaire as well as stated patient choice in the selection of approach for the third planned procedure of a series. These findings will be correlated with additional objective data regarding complication rates.
December, 2015 through August, 2016
To evaluate complication rates and severity from different modes of access.
December, 2015 through August, 2016
To assess ancillary procedural and patient satisfaction quality metrics between the two groups.
December, 2015 through August, 2016
To identify potential risk factors for complications in transradial approach.
December, 2015 through August, 2016
Transarterial hepatic embolization of liver cancer
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Subjects will be patients referred to Division of Vascular Interventional Radiology (VIR) at MUSC found suitable for TACE per the Barcelona Clinic Liver Cancer Staging System with stage B disease (Eastern Cooperative Oncology Group (ECOG) performance status 0-2 and Child-Pugh A-B liver disease with or without portal vein thrombus). Our current institutional protocol to treat unresectable Hepatocellular Carcinoma(HCC) and hepatic metastatic includes three separate TACE/TAE procedures in average in order to obtain local tumor control.
Medical University of South Carolina
Charleston, South Carolina, 29425, United States
55 participants (actual enrollment reported by the registry).
First Submitted
May 19, 2017
First Posted
May 22, 2017
Study Start
December 1, 2015
Actual (reported)Impact of Three-dimensional Visualization on Operation Strategy and Complications for Complex Hepatic Carcinoma
Contact the study team to confirm eligibility.
Primary Completion
April 20, 2016
Actual (reported)Study Completion
August 18, 2016
Actual (reported)Last Updated
May 22, 2017
Record last verified: 2017-05
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: